SC 13G: Avalo Therapeutics, Inc.

AI Summary

SC 13G filing by Avalo Therapeutics, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• avalo13g-05132024.htm (SC 13G) — 130KB
• 0001013594-24-000465.txt ( ) — 132KB

(a)

Item 1(a). Name of Issuer: Avalo Therapeutics, Inc. ("Issuer")

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 540 Gaither Road, Suite 400, Rockville, MD 20850

(a)

Item 2(a). Name of Persons Filing: The names of the persons filing this statement on Schedule 13G are (collectively, the "Reporting Persons"): Allostery Master Fund LP, a Cayman Islands exempted limited partnership ("Allostery Master Fund"); Allostery Investments LP, a Delaware limited partnership ("Allostery Investments"); Allostery Investments GP LLC, a Delaware limited liability company ("Allostery Investments GP"); Christopher Staral, a United States citizen ("Mr. Staral"); and David Modest, a United States citizen ("Mr. Modest").

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address of each of the Reporting Persons is One Stamford Plaza, 9th Floor, 263 Tresser Boulevard, Stamford, CT 06901.

(c)

Item 2(c). Citizenship: Allostery Master Fund LP is a Cayman Islands exempted limited partnership. Allostery Investments LP is a Delaware limited partnership. Allostery Investments GP LLC is a Delaware limited liability company. Messrs. Staral and Modest are citizens of the United States.

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.001 per share (the "Common Stock")

(e)

Item 2(e). CUSIP Number: 05338F306 Item 3. If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Exchange Act. (b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act. (c) [ ] Insurance company defined in Section 3(a)(19) of the Exchange Act. (d) [ ] Investment company registered under Section 8 of the Investment Company Act. (e) [ ] Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). (f) [ ] Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). (g) [ ] Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). (h) [ ] Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [ ] Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) [ ] Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J). (k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ Item 4. (a) Amount beneficially owned: As of May 1, 2024, Allostery Master Fund beneficially owned 78,255 shares of Common Stock. Allostery Investments, as the investment manager of Allostery Master Fund, may be deemed to have beneficially owned the 78,255 shares of Common Stock beneficially owned by Allostery Master Fund. Allostery Investments GP, as the general partner of Allostery Investments, may be deemed to have beneficially owned the 78,255 shares of Common Stock beneficially owned by Allostery Investments. Messrs. Modest and Staral, as the managing members of Allostery Investments GP, may be deemed to have beneficially owned the 78,255 shares of Common Stock beneficially owned by Allostery Investment GP. (b) Perce

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct. Dated: May 13, 2024 ALLOSTERY MASTER FUND LP By: Allostery Investments LP, its investment manager By: Allostery Investments GP LLC, its general partner By: /s/ David Modest David Modest, Managing Member ALLOSTERY INVESTMENTS LP By: Allostery Investments GP LLC, its general partner By: /s/ David Modest David Modest, Managing Member ALLOSTERY INVESTMENTS GP LLC By: /s/ David Modest David Modest, Managing Member /s/ Christopher Staral CHRISTOPHER STARAL /s/ David Modest DAVID MODEST EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Avalo Therapeutics, Inc. dated as of May 13, 2024, is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(2) under the Securities Exchange Act of 1934, as amended. Dated: May 13, 2024 ALLOSTERY MASTER FUND LP By: Allostery Investments LP, its investment manager By: Allostery Investments GP LLC, its general partner By: /s/ David Modest David Modest, Managing Member ALLOSTERY INVESTMENTS LP By: Allostery Investments GP LLC, its general partner By: /s/ David Modest David Modest, Managing Member ALLOSTERY INVESTMENTS GP LLC By: /s/ David Modest David Modest, Managing Member /s/ Christopher Staral CHRISTOPHER STARAL /s/ David Modest DAVID MODEST

View Full Filing

View this SC 13G filing on SEC EDGAR